Smartleaf Asset Management LLC Biotechnology

Smartleaf Asset Management LLC

$1.13 Trillion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
BCRX Biocryst Pharmaceuticals Inc	$1.29B	$2.72 Million 0.0% of portfolio	291	Q2 2025 Added 230.68%
BEAM Beam Therapeutics Inc.	$2.1B	$2.6 Million 0.0% of portfolio	155	Q2 2025 Reduced 30.8%
REPL Replimune Group, Inc.	$441M	$2.57 Million 0.0% of portfolio	275	Q2 2025 Reduced 63.09%
KYMR Kymera Therapeutics, Inc.	$3.31B	$2.47 Million 0.0% of portfolio	56	Q2 2025 Reduced 67.25%
SRPT Sarepta Therapeutics, Inc.	$2.04B	$2.26 Million 0.0% of portfolio	132	Q2 2025 Reduced 57.56%
PCVX Vaxcyte, Inc.	$2.51B	$1.95 Million 0.0% of portfolio	60	Q2 2025 Reduced 76.92%
ZLAB Zai Lab LTD	$2.81B	$1.74 Million 0.0% of portfolio	50	Q2 2025 New
ACLX Arcellx, Inc.	$3.75B	$1.37 Million 0.0% of portfolio	21	Q2 2025 Reduced 84.33%
ARWR Arrowhead Pharmaceuticals, Inc.	$4.07B	$1.19 Million 0.0% of portfolio	74	Q2 2025 Reduced 69.55%
RNA Avidity Biosciences, Inc.	$2.55B	$1.13 Million 0.0% of portfolio	39	Q2 2025 Reduced 56.67%
TARS Tarsus Pharmaceuticals, Inc.	$1.9B	$1.09 Million 0.0% of portfolio	27	Q2 2025 New
FOLD Amicus Therapeutics, Inc.	$2.37B	$990,000 0.0% of portfolio	167	Q2 2025 Reduced 63.62%
BGNE Bei Gene, Ltd.	$23.5B	$964,000 0.0% of portfolio	4	Q4 2024 Reduced 75.0%
FENC Fennec Pharmaceuticals Inc.	$222M	$907,000 0.0% of portfolio	110	Q4 2024 New
SRRK Scholar Rock Holding Corp	$1.45B	$823,000 0.0% of portfolio	23	Q2 2025 Reduced 87.15%
NUVL Nuvalent, Inc.	$4.21B	$796,000 0.0% of portfolio	10	Q2 2025 Reduced 88.64%
OCUL Ocular Therapeutix, Inc	$901M	$719,000 0.0% of portfolio	78	Q2 2025 Reduced 65.49%
NRIX Nurix Therapeutics, Inc.	$490M	$616,000 0.0% of portfolio	53	Q2 2025 Reduced 75.35%
ENTA Enanta Pharmaceuticals Inc	$230M	$532,000 0.0% of portfolio	71	Q2 2025 Reduced 83.64%
IMVT Immunovant, Inc.	$3.55B	$531,000 0.0% of portfolio	33	Q2 2025 Reduced 81.36%
SANA Sana Biotechnology, Inc.	$1.06B	$522,000 0.0% of portfolio	186	Q2 2025 Reduced 38.21%
SNDX Syndax Pharmaceuticals Inc	$881M	$461,000 0.0% of portfolio	51	Q2 2025 Reduced 91.93%
MDXG Mimedx Group, Inc.	$766M	$427,000 0.0% of portfolio	72	Q2 2025 Reduced 87.35%
RLAY Relay Therapeutics, Inc.	$846M	$382,000 0.0% of portfolio	116	Q2 2025 Reduced 87.51%
EWTX Edgewise Therapeutics, Inc.	$957M	$342,000 0.0% of portfolio	26	Q2 2025 Added 23.81%
NTLA Intellia Therapeutics, Inc.	$2.13B	$258,000 0.0% of portfolio	27	Q2 2025 Reduced 46.0%
IDYA Ideaya Biosciences, Inc.	$1.47B	$235,000 0.0% of portfolio	11	Q2 2025 Reduced 94.91%
CLDX Celldex Therapeutics, Inc.	$1.29B	$142,000 0.0% of portfolio	7	Q2 2025 New
SMMT Summit Therapeutics Inc.	$3.8B	$103,000 0.0% of portfolio	5	Q2 2025 New
DYN Dyne Therapeutics, Inc.	$878M	$86,000 0.0% of portfolio	9	Q2 2025 New
VERA Vera Therapeutics, Inc.	$818M	$67,000 0.0% of portfolio	3	Q2 2025 New
NVAX Novavax Inc	$688M	$63,000 0.0% of portfolio	10	Q2 2025 New
FATE Fate Therapeutics Inc	$149M	$36,000 0.0% of portfolio	35	Q1 2025 New
DAWN Day One Biopharmaceuticals, Inc.	$544M	$32,000 0.0% of portfolio	5	Q2 2025 Reduced 79.17%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Smartleaf Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Smartleaf Asset Management LLC with notifications on news.